We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 575

Pre-revenue Biotech Companies Can Apply For Listing In Hong Kong With Effect From 30 April 2018
  • Baker McKenzie
  • Hong Kong
  • April 26 2018

On 24 April 2018, The Stock Exchange of Hong Kong Limited (HKEx) published its Consultation Conclusions to HKEx's proposals to expand Hong Kong's

Hong Kong Announces Groundbreaking New Rules for Dual-Class Share, High-Tech and Biotech Company Listings
  • Skadden Arps Slate Meagher & Flom LLP
  • Hong Kong
  • February 26 2018

After publishing the “New Board Concept Paper Conclusions” in December 2017, the Stock Exchange of Hong Kong Limited (the Exchange) issued on 23

Trade Secrets Protection Reinforced
  • HFG Law & Intellectual Property
  • USA, Australia, China
  • January 31 2018

On January 1st, 2018, the new Amendment to the PRC Anti-Unfair Competition Law (the "Amended AUCL") has entered into force. AUCL has always been a

Cyber Risk News & Trends - December 2017
  • Buchanan Ingersoll & Rooney PC
  • USA
  • December 5 2017

Internet data breaches threaten the usernames and passwords of billions of people, but bad actors find phishing is the most effective way to hijack

Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon

Ninth Circuit Analyzes Statements Concerning FDA Feedback, in In re Atossa Genetics, Inc. Securities Litigation (August 18, 2017)
  • Lane Powell PC
  • USA
  • October 4 2017

On August 18, 2017, a Ninth Circuit panel affirmed in part, reversed in part, and vacated in part the district court's dismissal of the amended

Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • September 27 2017

The U.S. Supreme Court resolved a circuit split by deciding that the three-year limit for filing lawsuits under Section 13 of the Securities Act is a

Global Privacy & Cybersecurity Update Vol. 15
  • Jones Day
  • USA, European Union, Global
  • September 13 2017

On June 19, the Federal Trade Commission ("FTC") submitted comments to a working group organized by the Department of Commerce's National

FDA Trip Leads to Securities Stumble: The Gravity of Regulatory Due Diligence
  • Arent Fox LLP
  • USA
  • September 7 2017

After three years of litigation, a medical device manufacturer has agreed to pay $7 million to settle a class action lawsuit that claimed the company

First Circuit Affirms Dismissal Of Putative Securities Fraud Class Action, Finding Defendants’ Statements Concerning The Potential NDA For A Drug Candidate Came “Replete with Caveats”
  • Shearman & Sterling LLP
  • USA
  • August 29 2017

On August 22, 2017, the United States Court of Appeals for the First Circuit affirmed an order from the District of Massachusetts, dismissing a